Clinical Trials · NCT00535860
Efficacy & Safety of ViaDerm-hPTH(1-34) Compared to Forteo SC in Postmenopausal Women With Osteoporosis
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- TransPharma Medical
- Enrollment
- 104
- Start date
- Apr 2008
- Locations
- 10 sites, 3 countries
- Primary endpoint
- Change from baseline to endpoint 96 days in procollagen 1 N-terminal propeptide (P1NP)